Vimla Band
Affiliations: | Interdepartmental Biological Sciences Program | Northwestern University, Evanston, IL |
Area:
Molecular Biology, Cell BiologyGoogle:
"Vimla Band"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Luan H, Bielecki TA, Mohapatra BC, et al. (2023) EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry. Elife. 12 |
| Luan H, Bailey TA, Clubb RJ, et al. (2021) CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation. Cancers. 13 |
| Vellichirammal NN, Albahrani A, Banwait JK, et al. (2020) Pan-Cancer Analysis Reveals the Diverse Landscape of Novel Sense and Antisense Fusion Transcripts. Molecular Therapy. Nucleic Acids. 19: 1379-1398 |
| Tom EC, Mushtaq I, Mohapatra BC, et al. (2020) EHD1 and RUSC2 control basal EGFR cell surface expression and recycling. Molecular and Cellular Biology |
| Zhao Y, Alakhova DY, Zhao X, et al. (2019) Eradication of Cancer stem cells in triple negative breast Cancer using Doxorubicin/Pluronic polymeric micelles. Nanomedicine : Nanotechnology, Biology, and Medicine. 102124 |
| Wu VT, Kiriazov B, Koch KE, et al. (2019) A TFAP2C Gene Signature is Predictive of Outcome in HER2-positive Breast Cancer. Molecular Cancer Research : McR |
| Song H, Zeng J, Roychoudhury S, et al. (2019) Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer. Molecular Cancer Therapeutics |
| Gautam SK, Kanchan R, Atri P, et al. (2019) Abstract 2017: Blocking ErbB-c-Met-FAK signaling axis suppresses brain metastasis of breast cancer Cancer Research. 79: 2017-2017 |
| Wang Y, Shi W, Kuss M, et al. (2018) 3D Bioprinting of Breast Cancer Models for Drug Resistance Study. Acs Biomaterials Science & Engineering. 4: 4401-4411 |
| Ali R, Al-Kawaz A, Toss MS, et al. (2018) Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. Cancer Research |